CME GroupCME -4.41%81 Altman Z2-Score is 0.53 as of Jun. 24, 2026, which is 23% below its 10-year median of 0.69. GuruFocus rates CME with a GF Score™ of 81/100 and a GF Value™ of $270.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 689 Capital Markets companies, CME Group ranks worse than 80.99% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Warning Sign:
CME Group has a Altman Z2-Score of 0.53, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for CME Group's Altman Z2-Score or its related term are showing as below:
CME'
s Altman Z2-Score Range Over the Past 10 Years
Min: 0.42 Med: 0.69 Max: 1.35
Current: 0.53
During the past 13 years, CME Group's highest Altman Z2-Score was 1.35. The lowest was 0.42. And the median was 0.69.
CME Group (NAS:CME) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
CME Group Altman Z2-Score Related Terms
CME Group Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for CME Group's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Financial Data & Stock Exchanges subindustry, CME Group's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CME Group Altman Z2-Score vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CME Group's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where CME Group's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
CME Group's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.0149
+
3.26
*
0.0242
+
6.72
*
0.0286
+
1.05
*
0.1518
=
0.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
CME Group (CME) has a Altman Z2-Score of 0.53 as of Jun. 24, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on CME Group and its competitors. This is 23% below median its historical median of 0.69. Over the past decade, CME Group's Altman Z2-Score has ranged from 0.42 to 1.35. According to the industry distribution chart, CME Group ranks #558 out of 689 companies in the Capital Markets industry, placing it in the top 81%.
Is CME Group's Altman Z2-Score too high?
CME Group's current Altman Z2-Score of 0.53 is 23% below median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 1.35. The Capital Markets industry median Altman Z2-Score is 4.27. CME Group's value of 0.53 is 87.6% below this industry median. Based on the distribution chart, CME Group ranks #558 out of 689 companies in the Capital Markets industry, which is in the bottom quartile relative to peers. Overall, CME Group has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CME Group's Altman Z2-Score compare to ICE and MCO?
According to the Capital Markets industry distribution chart, CME Group ranks #558 out of 689 companies for Altman Z2-Score. This places CME Group in the lower half of its industry. The industry median Altman Z2-Score is 4.27. CME Group's value of 0.53 is 87.6% below this benchmark. Historically, CME Group's own Altman Z2-Score has ranged from 0.42 to 1.35 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 4.27, CME Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Capital Markets company?
The median Altman Z2-Score among Capital Markets companies is 4.27, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CME Group's current Altman Z2-Score of 0.53 is 87.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on CME Group and its competitors. For the Capital Markets industry, the median Altman Z2-Score is 4.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CME Group's current Altman Z2-Score is 0.53, which is 23% below median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Modestly Undervalued. The stock's GF Value™ is $270.89, compared to a current price of $231.68 — trading 14.5% below its estimated fair value. The current Altman Z2-Score is 0.53, which is 23% below median its 10-year median of 0.69 and 87.6% below the Capital Markets industry median of 4.27. CME Group's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For CME Group (CME), the current Altman Z2-Score is 0.53 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CME Group (CME) Overvalued in 2026?
Based on GuruFocus' analysis, CME Group stock appears to be undervalued.
The current stock price of $231.68 is trading 14.5% below its estimated GF Value™ of $270.89.
GuruFocus considers CME Group to be Modestly Undervalued.
Key valuation signals for CME:
Altman Z2-Score: 0.53 (23% below median its 10-year median of 0.69)
GF Value™: $270.89 vs. price of $231.68 (14.5% below fair value)
Industry Position: 87.6% below the Capital Markets median (#558 of 689)
No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
81GF Score
Get the complete analysis for CME
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CME has been successfully added to your 
